Entera Bio (ENTX) Cash & Current Investments (2017 - 2026)

Entera Bio (ENTX) has reported Cash & Current Investments for 10 consecutive years, with $4.1 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Current Investments fell 67.1% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 67.1% YoY) and the FY2025 annual result came in at $14.9 million, up 71.86% from the prior year.
• Cash & Current Investments slipped to $4.1 million in Q1 2026 per ENTX's latest filing, from $14.9 million in the prior quarter.
• Over the last five years, Cash & Current Investments for ENTX reached as high as $20.1 million in Q1 2022 and fell as low as $4.1 million in Q1 2026.
• A 5-year average of $11.0 million and a median of $10.7 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2025 — Cash & Current Investments jumped 71.86% — and 2026, when it plunged 67.1%.
• Year by year, Cash & Current Investments stood at $12.3 million in 2022, then retreated by 10.48% to $11.0 million in 2023, then slipped by 21.41% to $8.7 million in 2024, then soared by 71.86% to $14.9 million in 2025, then slumped by 72.2% to $4.1 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $4.1 million, $14.9 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.